Craig Hallum initiated coverage on Myomo with a new price target
$MYO
Industrial Specialties
Health Care
Craig Hallum initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/31/2024 | $7.00 | Buy | Craig Hallum |
| 5/20/2024 | $7.00 | Buy | Lake Street |
| 12/15/2023 | $6.50 | Buy | H.C. Wainwright |
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of William "Will" Febbo as a director effective April 14, 2026, to serve until the 2028 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Febbo is an accomplished executive, entrepreneur, and investor with over 30 years of experience in healthcare, financial services, and technology-driven businesses. He has successfully guided organizations through substantial growth, strategic transformations and acquisitions, and significant ca
Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has entered into its first among a series of expected network participation agreements with Elevance Health. The contracts, which include the Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans are expected to become effective on a market-by-market basis through the second quarter of 2026. Once complete, the addition of these 45 million medical members will bring Myomo's total number of covered lives under commercial insurance plans to over 80 million. These a
4 - MYOMO, INC. (0001369290) (Issuer)
4 - MYOMO, INC. (0001369290) (Issuer)
4 - MYOMO, INC. (0001369290) (Issuer)
8-K - MYOMO, INC. (0001369290) (Filer)
144 - MYOMO, INC. (0001369290) (Subject)
S-8 - MYOMO, INC. (0001369290) (Filer)
4 - MYOMO, INC. (0001369290) (Issuer)
3 - MYOMO, INC. (0001369290) (Issuer)
4/A - MYOMO, INC. (0001369290) (Issuer)
Craig Hallum initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00
Lake Street initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00
H.C. Wainwright initiated coverage of Myomo with a rating of Buy and set a new price target of $6.50
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of William "Will" Febbo as a director effective April 14, 2026, to serve until the 2028 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Febbo is an accomplished executive, entrepreneur, and investor with over 30 years of experience in healthcare, financial services, and technology-driven businesses. He has successfully guided organizations through substantial growth, strategic transformations and acquisitions, and significant ca
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin
Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after
Revenue of $10.1 million 229 authorizations and orders, highest number this year Reiterates full year revenue guidance of $40 million to $42 million Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and nine months ended September 30, 2025. "Third quarter revenues were at the high end of our expectations, with International and U.S. orthotics and prosthetics ("O&P") revenues at record levels. Revenue increased while operating expenses decrease
SC 13G/A - MYOMO, INC. (0001369290) (Subject)
SC 13G/A - MYOMO, INC. (0001369290) (Subject)
SC 13G/A - MYOMO, INC. (0001369290) (Subject)